Ali MS, Berencsi K, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Lapi F, Simonetti M, Reyes C, Van der Lei J, Sturkenboom M, Prieto-Alhambra D. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int. 2020 Dec;31(12):2425-38.
Gilsenan A, Harris D, Reynolds M, McSorley D, Midkiff K, Jackson L, Muldavin B, Kellier-Steele N, Andrews E. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporos Int. 2020 Nov 5;32(4):645-51. doi: 10.1007/s00198-020-05718-0
Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int. 2020 Apr;31(4):721-55. doi: 10.1007/s00198-020-05314-2
Mody FV, Goyal RK, Ajmera M, Cainzos-Achirica M, Davis KL, Lindstrom RC, Globe G, Riebman JB, Wirtz HS, Amin A. Exploring the association between heart rate control and patient outcomes: a retrospective medical record review of patients hospitalized with systolic heart failure. Poster presented at the 2019 Heart Failure Society of America 23rd Annual Scientific Meeting; September 14, 2019. Philadelphia, PA. [abstract] J Card Fail. 2019 Aug; 25(8 Supplement):S156. doi: 10.1016/j.cardfail.2019.07.447
Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo patient registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018 Oct;29(10):2335-43. doi: 10.1007/s00198-018-4604-8
Camplain R, Kucharska-Newton A, Loehr L, Keyserling TC, Layton JB, Wruck L, Folsom AR, Bertoni AG, Heiss G. Accuracy of self-reported heart failure. The Atherosclerosis Risk in Communities (ARIC) Study. J Card Fail. 2017 Nov;23(11):802-8. doi: 10.1016/j.cardfail.2017.09.002
Hoffman V, Xue F, Gardstein B, Skerry K, Critchlow CW, Enger C. Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data. Osteoporos Int. 2016 Apr;27(4):1653-8. doi: 10.1007/s00198-015-3402-9
Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z
Overman RA, Gourlay ML, Deal CL, Farley JF, Brookhart MA, Layton JB. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporos Int. 2015 May;26(5):1515-24. doi: 10.1007/s00198-014-3022-9
McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011 Jul 1;22(7):2083-98.
Tosteson AN, Do TP, Wade SW, Anthony MS, Downs RW. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int. 2010 Oct;21(10):1769-80. doi: 10.1007/s00198-009-1133-5
Gutierrez L, Roskell N, Rycroft C, Castellsague J, Beard S, Abeysinghe S, Shannon P, Robbins S, Gitlin M. Economic and clinical burden of non-vertebral non-hip (Nvnh), vertebral and multiple fractures in postmenopausal women in the United Kingdom. Poster presented at IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; May 2010. Florence, Italy. [abstract] Osteoporos Int. 2010 May 1; 21(Suppl. 1):S96.
Castellsague J, Roskell N, Gutierrez L, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M. Economic and clinical burden of hip fractures in postmenopausal women in the United Kingdom (UK). Poster presented at the IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; May 2010. Florence, Italy. [abstract] Osteoporos Int. 2010 May 1; 21(Suppl. 1):S95.
Barrett-Connor E, Ensrud K, Tosteson AN, Varon SF, Anthony M, Daizadeh N, Wade S. Design of the POSSIBLE US trade mark study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int. 2009 Mar;20(3):463-72. doi: 10.1007/s00198-008-0674-3
Clarkson TB, Cline JM, Williams JK, Anthony MS. Gonadal hormone substitutes: effects on the cardiovascular system. Osteoporos Int. 1997;7(Suppl 1):543-51.